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Abstract
Background: Analgesic drugs are recommended to treat pain caused by osteoarthritis, and joint replacement
should decrease the need for them. We aimed to determine the user rates of analgesic drugs before and after joint
replacement.
Methods: All patients who underwent a primary hip or knee replacement for osteoarthritis from 2002 to 2013 in a
region of 0.5 million people were identified. Patients with revision or other joint replacements during the study
period (operation date +/− two years) were excluded, leaving 6238 hip replacements (5657 patients) and 7501 knee
replacements (6791 patients) for analyses. Medication data were collected from a nationwide Drug Prescription
Register and the prevalence (with its 95% confidence intervals) of acetaminophen, non-steroidal anti-inflammatory
drugs (NSAIDs), mild opioids, strong opioids, and medications used for neuropathic pain was calculated in three-
month periods two years before and after surgery.
Results: Between two years and three months preoperatively, the proportion of patients who redeemed at least
one type of analgesic drug increased from 28% (95% CI, 27–30%) to 48% (47–50%) on hip replacement patients
and from 33% (32–34%) to 41% (40–42%) on knee replacement patients. Postoperatively, the proportions decreased
to 23% (22–24%) on hip and to 30% (29–31%) on knee patients. Hip replacement patients used more NSAIDs (34%
(32–35%) hip vs 26% (25–27%) knee, p < 0.001), acetaminophen (14% (13–15%) vs 12% (11–13%), p < 0.001), and
mild opioids (14% (13–15%) vs 9% (8–9%), p < 0.001) than knee patients preoperatively, but postoperatively hip
patients used less NSAIDs (12% (11–13%) vs 16% (15–16%), p < 0.001), acetaminophen (9% (8–10%) vs 11% (11–12%),
p < 0.001), and mild opioids (5% (5–6%) vs 8% (7–8%), p < 0.001).
Conclusion: Use of analgesic drugs increases prior to joint replacement, and is reduced following surgery. However, a
considerable proportion of patients continue to use analgesics in two-year follow-up.
Keywords: Arthroplasty, Analgesics, Drug prescriptions, Opioids, Non-steroidal anti-inflammatory drugs,
Acetaminophen
Background
Pain is the most common symptom of osteoarthritis
(OA), and current guidelines for the management of
hip and knee OA recommend the use of both non-
pharmacological and pharmacological treatment op-
tions [1–5]. For those patients who do experience
insufficient pain relief with conservative treatment,
joint replacement is recommended [6–8]. Neverthe-
less, 8 to 27% of knee replacement and 5 to 21% of
hip replacement recipients suffer from persistent
postoperative pain [9].
At present, it is not completely known what propor-
tion of patients use analgesic drugs before and after joint
replacement. It has been estimated that nearly half of all
knee osteoarthritis patients use pain medication, mostly
over-the-counter (OTC) or prescription non-steroidal
anti-inflammatory drugs (NSAID) and acetaminophen
[10]. Supposedly, the proportion of patients using pain
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medication would be greater in those waiting for joint
replacement, and it should decrease postoperatively. The
proportion of hip and knee replacement recipients using
analgesic drugs preoperatively varies from 48 to 94%, de-
pending on methodology of the study [11–15] . The
most commonly used drugs are acetaminophen,
NSAIDs, and mild opioids [11–15]. These practices are
also in accordance with current guidelines for the
pharmacological treatment of osteoarthritis [1, 2, 4].
Several recent studies have examined opioid use after
joint replacement [16–18], but only a few studies have ex-
amined overall analgesic consumption both before and after
surgery [11, 13, 15, 19–21]. Prescription data on total hip
replacement patients indicate an increase in the use of anal-
gesics (both opioids and non-opioids) during the year be-
fore surgery, followed by a peak occurring immediately
after surgery and then a decrease during the first postopera-
tive year [13]. In the field of knee replacement, again, previ-
ous studies have mainly focused on the risk factors for
increased postoperative analgesic consumption [11, 15, 19,
21] or only on the consumption of NSAID’s [20]. More-
over, only a few studies have included medications used for
neuropathic pain [11, 13–15, 18], although a remarkable
share of joint replacement patients suffer from persistent
postoperative pain [9] that may be treated with such drugs.
Therefore, research on the consumption of analgesic drugs
in joint replacement patients should include all analgesic
drugs, and not only acetaminophen, NSAID’s, and opioids.
The aim of this study was to provide a detailed description
of consumption trajectories for all prescription analgesic
drugs two years before and after hip or knee replacement.
Methods
The study population
All hip and knee replacement operations in the Pir-
kanmaa hospital district (population 0.5 million) in
Finland are performed in a single orthopedic hospital.
Between 2 September 2002 and 31 December 2013,
26,466 operations (13,261 hip replacements and 13,
205 knee replacements) were performed on 20,068
patients at the hospital. Preoperative and postopera-
tive information on these patients was collected from
the prospective joint replacement database of the hos-
pital. In this study, the inclusion criteria were primary
operation and primary osteoarthritis being the indica-
tion for surgery. Patients with revisions or other joint
replacements during the study period (operation date
+/− two years) were excluded, leaving 6238 hip re-
placements (5657 patients) and 7501 knee replace-
ments (6791 patients) for analyses (Fig. 1).
Medication data
In Finland, the conservative treatment of osteoarthritis
is primarily the responsibility of general practitioners. If
conservative treatment is insufficient, patients are re-
ferred for consideration for joint replacement [5]. Post-
operatively, analgesics are first prescribed by surgeons,
whereas general practitioners prescribe analgesics in
longer follow-up.
All medications in Finland are dispensed from licensed
pharmacies. The Social Insurance Institution of Finland
maintains a nationwide Drug Prescription Register that
contains information on all prescribed medications that
have been dispensed in Finland. In this study, informa-
tion on the Anatomical Therapeutic Chemical (ATC)
code of dispensed drugs, the number of units dispensed
(tablets or patches), and the date of purchase was col-
lected from the Drug Prescription Register. Prescription
data were linked to joint replacement data using the
unique personal identification code assigned to all
Finnish residents.
The included medications were classified into
subgroups according to their ATC codes as follows: acet-
aminophen (N02BE01), non-steroidal anti-inflammatory
drugs (NSAID) (M01A), mild opioids (N02AA59,
N02AX02, N02AE01), strong opioids (N02AA01, N02AA03,
N02AA05, N02AB03), medications used for neuropathic
pain (N03AX12, N03AX16, N06AA09, N06AA10,
N06AX16, N06AX21, i.e., gabapentin, pregabalin, amitrip-
tyline, nortriptyline, venlafaxine, and duloxetine), and any
analgesic drug (all previous groups combined). Trans-
dermal buprenorphine patches were classified as mild
opioids and transdermal fentanyl patches were classi-
fied as strong opioids. Oral buprenorphine and fen-
tanyl as well as oral liquid products of all opioids
were excluded because they are used for pain caused
by other reasons than osteoarthritis, like cancer pain.
Transdermal gel products and oral liquid products of
NSAID’s were excluded from this study.
Statistics
The proportions (with 95% confidence intervals) of pa-
tients who redeemed at least one prescription of a medi-
cation were calculated in time-periods of three months
(90 days) during the 4-year observation period. Three-
month periods were chosen because Finnish pharmacies
are only allowed to give patients a 90-day supply of pre-
scribed medication at a time. It was recorded, whether a
patient had redeemed at least one prescription of a stud-
ied medication at a corresponding quartile. The eight
quartiles before the operation are referred to as the pre-
operative period and the eight quartiles after the oper-
ation as the postoperative period.
The primary outcome was the detailed description of
the analgesic consumption trajectories of the various
drug classes two years before and after surgery. An ex-
pression ‘user rate’ is used as a synonym for the propor-
tion of patients who redeemed drugs in a specific time-
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period. Analgesic consumption on late preoperative
period (three months preoperatively) was compared to
early preoperative consumption (two years preopera-
tively) and late postoperative (two years postoperatively)
consumption. The primary outcome was first analyzed
in the whole study population and then in the subgroups
according to joint (hip versus knee), gender, and age (<
65 years, 65 to 75 years, > 75 years). Finally, an additional
analysis was made to determine the proportions of pa-
tients who continued to use analgesic drugs after surgery
and the proportion of patients who were new users. In
this analysis, the patients were divided into subgroups
based on information whether they had redeemed anal-
gesics during the year before surgery or not.
The analyses were performed using IBM SPSS Statis-
tics 24. Bilateral operations were analyzed as one. Para-
metric variables are presented with mean and standard
deviation (SD) and categorical variables with numbers
and percentages. Unpaired T-test was used to compare
parametric variables and chi-square test was used to
compare categorical variables. P-values of < 0.05 were
considered statistically significant.
Results
Study population
The study population was an unselected population-
based cohort of OA patients undergoing joint replace-
ment surgery. The mean age was 68.7 years (SD 10.1)
and majority (61%) were women (Table 1). Knee re-
placement patients were older and more often women
than hip patients (Table 1). A bilateral operation was
performed in 7% of hip and 16% of knee replace-
ments patients.
All patients
During the 4-year observation period, 92% (95% CI,
91–93%) of the hip replacement patients and 94%
(93–94%) of the knee replacement patients redeemed
at least one analgesic drug prescription.
Table 1 Demographic characteristics
Hip replacement Knee replacement
Total number, n (%) 6238 7501
Gender, female, n (%) 3319 (53.2%) 5077 (67.7%)
Age, mean (SD), years 67.6 (10.6) 69.7 (9.5)
Bilateral operation, n (%) 418 (6.7%) 1225 (16.3%)
BMIa, mean (SD), years 28.2 (4.7) 29.9 (4.8)
Diabetes 473 (7.6%) 744 (9.9%)
Neurodegenerative diseaseb 86 (1.4%) 111 (1.5%)
Cardiac diseasec 699 (11.2%) 904 (12.1%)
Pulmonary disease 373 (6.0%) 619 (8.3%)
Hypertension 1656 (26.5%) 2491 (33.2%)
Epilepsy 67 (1.1%) 74 (1.0%)
History of malignancy 182 (2.9%) 273 (3.6%)
ASA score
1 637 (10.2%) 373 (5.0%)
2 2398 (38.4%) 2910 (38.8%)
3 1766 (28.3%) 2590 (34.5%)
4 90 (1.4%) 97 (1.3%)
missing 1347 (21.6%) 1531 (20.4%)
SD = standard deviation
aBody mass index; missing information on 866 (13.9%) of hip and 1042
(13.9%) of knee replacement patients
bAlzheimer’s or Parkinson’s disease
ccoronary artery disease, heart failure, chronic arrythmia
Fig. 1 Flowchart
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The proportion of patients who redeemed at least one
type of analgesic drug prescription increased before the
surgery (Fig. 2, Table 2). Two years before the surgery,
28% (27–30%) of hip patients and 33% (32–34%) of knee
patients redeemed a prescription for at least one type of
analgesic drug. By three months before the surgery, the
proportions had increased to 48% (47–50%) and 41% (40–
42%). After surgery, the use of all analgesics declined and
the user rates decreased approximately to the level 2 years
before surgery (Fig. 2, Table 2). The preoperative increase
was especially attributable to the use of acetaminophen,
NSAID’s, and mild opioids in hip patients and to acet-
aminophen and mild opioids in knee patients. The pro-
portion of patients using NSAIDs decreased in both hip
and knee patients in the late preoperative period (Fig. 2).
In supplementary analysis, the drug use was analyzed in
one year periods, and 73% (72–74%) of hip patients and
67% (66–68%) of knee patients redeemed at least one pre-
scription one year before the surgery (Appendix 1).
A peak in the number of patients who redeemed medi-
cation was seen in the immediate postoperative period
for all analgesic drugs. After the immediate postopera-
tive period, fewer hip patients redeemed analgesics (ex-
cept strong opioids) than knee patients: Two years after
surgery any analgesics were redeemed by 23% of hip and
30% of knee patients (p < 0.001), acetaminophen by 9%
of hip and 11% of knee patients (p < 0.001), NSAID by
12% of hip and 16% of knee patients, mild opioid by 5%
of hip and 8% of knee patients (p < 0.001) and
medication used for neuropathic pain by 3% of hip and
4% of knee patients (p < 0.001) (Fig. 2).
The most common analgesic drugs throughout the
study period were NSAIDs, except on patients > 75
years old who redeemed more often acetaminophen
than NSAID’s in the late postoperative period (Table
2). Three months before the surgery, 34% (95% CI:
32–35%) of hip replacement patients and 26% (25–
27%) of knee patients redeemed NSAIDs, followed by
acetaminophen (14% (13–15%) of hip patients and
12% (11–13%) of knee patients), mild opioids (14%
(13–15%) and 9% (8–9%)), medications used for
neuropathic pain (3% (3–4%) and 4% (3–4%)), and
strong opioids (0.5% (0.3–0.6%) and 0.4% (0.3–0.5%),
respectively) (Table 2).
Those patients who had redeemed analgesics pre-
operatively also redeemed them more often postoper-
atively compared to those patients who had not
redeemed analgesics preoperatively (p < 0.001)
(Table 3). Of the patients who had not redeemed an-
algesics three months preoperatively, a higher propor-
tion of knee patients (19%) than hip replacement
patients (13%) redeemed any analgesics two years
postoperatively (p < 0.001).
Gender
In both operation types, the proportions of patients
who redeemed at least one type of analgesic drug,
acetaminophen, NSAIDs, and mild opioids, were
Fig. 2 The proportions of patients with prescription analgesic drugs in three months intervals.NSAID;nonstereriod anti-inflammatory drug
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higher in women than men during the whole study
period, with the only exception being the immediate
postoperative period (Appendix 2, Table 2). During
the study period, the proportion of patients who
redeemed medications used for neuropathic pain was
higher in women than in men, whereas there were no
differences in the use of strong opioids, except on
late postoperative period (Appendix 2, Table 2).
Age
The proportion of patients who redeemed acetamino-
phen was higher in older age groups (compared to
the youngest age group) (Table 2). A higher propor-
tion of younger patients redeemed NSAID’s. In older
patients, the proportion of patients who had
redeemed at least one type of analgesic drug was
higher after surgery compared to younger patients
Table 3 The proportions of hip and knee replacement patients who continued to redeem analgesicsa or were new to redeem
analgesicsb postoperatively
Preoperative Proportion of patients who redeemed analgesics postoperatively
0–3 months preop 0–3 months postop 3–6 months postop 9–12 months postop 21–24 months postop
Any analgesic drug
Preoperative usea 6058 5141
(84.9%)
2933
(48.4%)
2591
(42.8%)
2424
(40.0%)
No preoperative useb 7681 5205
(67.8%)
1331
(17.3%)
1187
(15.5%)
1258
(16.4%)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Acetaminophen
Preoperative usea 1764 1162
(65.9%)
669
(37.9%)
569
(32.3%)
507
(28.7%)
No preoperative useb 11,975 3796
(31.7%)
881
(7.4%)
812
(6.8%)
896
(7.5%)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
NSAID
Preoperative usea 4078 2947
(72.3%)
1440
(35.3%)
1211
(29.7%)
1032
(25.3%)
No preoperative useb 9661 5181
(53.6%)
1102
(11.4%)
912
(9.4%)
885
(9.2%)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Mild opioid
Preoperative usea 1510 903
(59.8%)
476
(31.5%)
414
(27.4%)
384
(25.4%)
No preoperative useb 12,229 3159
(25.8%)
549
(4.5%)
452
(3.7%)
521
(4.3%)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Strong opioid
Preoperative usea 58 34
(58.6%)
24
(41.4%)
24
(41.4%)
16
(27.6%)
No preoperative useb 13,681 251
(1.8%)
30
(0.2%)
39
(0.3%)
30
(0.2%)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Medication used for neuropathic pain
Preoperative usea 454 278
(61.2%)
275
(60.6%)
283
(62.3%)
246
(54.2%)
No preoperative useb 13,285 165
(1.2%)
168
(1.3%)
197
(1.5%)
252
(1.9%)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
aThe number of patients who had redeemed drugs 3 months preoperatively. The following numbers represent how many of them continued to redeem drugs in
different time periods postoperatively (i.e. old users)
bThe number of patients who had not redeemed drugs 3 months preoperatively. The following numbers represent how many of them redeemed drugs in
different time periods postoperatively (i.e. new users)
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(Table 2). The difference according to age was mostly
attributable to hip surgery: two years after surgery
20% of patients < 65 years, 22% of patients 65–75
years, and 28% of patients > 75 years redeemed any
analgesics (p < 0.001), compared to 31, 29, and 30%
(p = 0.609), respectively.
Discussion
This large, regionally all-inclusive study of primary
hip and knee replacement patients with primary
osteoarthritis shows an increase in the proportion of
patients using analgesic drugs before surgery, a peak
in use during the immediate postoperative period,
and a decrease in the late postoperative period. A
surprisingly large share of patients does not use any
analgesics preoperatively. However, those who use an-
algesics preoperatively, are more likely to use them
also postoperatively, and one-fifth of hip and almost
one-third of knee replacement recipients still use an-
algesics two years after surgery. These results expand
the existing knowledge [13] by showing prescription
trajectories have similar pattern in hip and knee re-
placements but use of analgesics is more common in
knee than hip replacement patients after surgery. Use
of strong opioids and drugs for neuropathic pain was
rare and mostly limited to patients who were using
these agents already before surgery.
The observed user rates of analgesic drugs were lower
than in earlier studies [12–14, 20]. Variations in study de-
signs may be one explaining factor. Some patients may have
used only OTC drugs, leading to underestimation of user
rates. Although approximately one-fourth of all NSAIDs
are bought over-the-counter [22], the share is probably
clearly smaller on patients with chronic painful conditions,
like osteoarthritis, because in Finland only small packs of
acetaminophen, ibuprofen, and ketoprofen are available
OTC and they are more expensive than prescribed analge-
sics. Furthermore, it is unlikely that the use of OTC drugs
could explain the differences of user rates between studied
groups of patients. Nevertheless, in accordance with earlier
studies [13, 20], there is indeed a surprisingly large propor-
tion (27%) of patients who did not redeem any prescription
analgesic drugs during the year before surgery, although
pain is the crucial indication for joint replacement [1, 4].
One explanation could be that in some patients the func-
tional impairment and deformity of the operated joint ra-
ther than pain has been the main indication for surgery.
Additionally, only half of the knee osteoarthritis patients
have constant pain, instead, the pain in knee osteoarthritis
is typically intermittent weight-bearing pain, and quite
often it is unpredictable, too [23, 24].
The proportions of patients using acetaminophen,
NSAIDs, and opioids in the late postoperative period were
surprisingly high both after hip and knee replacement,
again in line with earlier studies [13–15, 17, 18]. The user
rates of NSAIDs decreased to a lower level postoperatively
than that observed two years preoperatively whereas a
small increase was found in acetaminophen, mild opioids,
and medications used for neuropathic pain. A possible ex-
planation is persistent postoperative pain which is more
common after knee replacement and may affect even one
fifth of the patients [9]. Use of analgesics was greater in
women who are known to report more osteoarthritis pain
and acute procedural pain than men [22, 23]. They also
have more persistent postoperative pain [19, 25–27]. Al-
though patients with other joint replacements during the
follow-up period were excluded, a multi-joint osteoarth-
ritis and other chronic musculoskeletal conditions are a
very likely reason for prolonged analgesic use particularly
in the oldest age groups. Unlike some other countries,
however, addiction is an unlike explanation, because there
has not been an opioid epidemic in Finland and the user
rates of opioids were relatively small.
The proportion of patients who redeemed acetamino-
phen, NSAIDs, or mild opioids increased preoperatively
more in hip than in knee replacement patients. Postop-
eratively, the decrease was higher on hip patients,
which has been shown in NSAIDs before [20]. No
change in user rates was seen after 9 months in hip
replacement patients, but the user rates in knee re-
placement patients decreased until 12 months postoper-
atively, which may be related to the longer recovery
period after knee replacement. Furthermore, user rates
for all the studied medications were higher among knee
than hip replacement patients for the whole postopera-
tive follow-up period. A higher prevalence of persistent
postsurgical pain following knee replacement may at
least partly explain this finding [9].
NSAIDs were the most common analgesic drugs which is
in line with the results of previous studies and guidelines [1,
2, 4, 13, 15], although the user rates were somewhat lower
than in previous studies [12–14, 20, 28, 29]. Although the ef-
ficacy and safety of acetaminophen in the treatment of
chronic osteoarthritis pain has been questioned recently
[30–32], the drug is safe and widely used among osteoarth-
ritis patients [10, 11, 13–15]. In this study, it was the second
most commonly drug used, and like other analgesics, its use
was clearly reduced after surgery. Interestingly, approxi-
mately twice as many patients redeemed acetaminophen in
the late postoperative period than in the early preoperative
period. It is possible that especially in the oldest age-groups
patients have changed from NSAIDs to acetaminophen be-
cause of the risks related to chronic use of NSAIDs [33].
User rates of opioids were lower than expected.
Earlier, between 24 and 59% of patients have used
opioids (mild and strong opioids have usually been
analyzed together) 1 to 2 years before joint replace-
ment [11, 14, 16, 17, 29, 34], whereas in this study
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the proportions were around 15 and 10% in hip and
knee patients three months before surgery, respect-
ively. Similar observation was made also when drug
use was analyzed for one year period. The reason for
this difference is unclear. Although it should be noted
that these results originate from one hospital district,
it seems that at population level the overall preva-
lence of dispensed opioids is lower in Finland (6% in
year 2016) [35] than in other Nordic countries (8–
12% in women and 6–9% in men in year 2016) [36]
or in the United States (17% in year 2017) [37]. Also,
the total consumption of opioid analgesics measured
in DDD has been lower in Finland [38]. Another ex-
planation might be that opioid prescription has been
controlled more tightly in Finland than in some other
countries, and a special prescription form which is
not possible to copy was needed for strong opioids at
the time of this study. All in all, the prevalence of
any opioid use was higher in our cohort compared to
Finnish population, which is in line with earlier find-
ings (in Sweden 9.6% on individuals without OA
compared to 23.7% on individuals with OA) [39].
It is noteworthy, that the number of long-term
users of opioids did not increase remarkably after
joint replacement, and only a minority of patients
were new users of opioids 2 years after hip and knee
replacement (3 and 5%, respectively). The consump-
tion of opioids was mostly related to the perioperative
phase. Use of strong opioids was rare (less than
0.5%), and only a minority were new users of strong
opioids after surgery (0.2%).
Unlike the other analgesics, the user rates of medi-
cation used for neuropathic pain did not have a clear
association with the time of surgery, suggesting that
the indication for the use of these drugs is probably
other than osteoarthritis. However, it has been esti-
mated that a neuropathic component is present in
one-third of patients with painful osteoarthritis [40,
41] and some patients could benefit from medication
used for neuropathic pain. In line with earlier studies
[11, 15], the user rates increased during the study
period, especially in knee replacement patients. Pro-
longed postoperative pain is a possible explanation for
this observation [9, 42].
There are several strengths in this register study, in-
cluding the large sample size of an unselected popula-
tion sample undergoing hip or knee replacement for
osteoarthritis. Medication data were extracted from a
publicly funded nationwide prescription register with
practically complete coverage. Only a few studies have
analyzed data of all analgesic drug classes from national
registers [11, 13, 15]. We believe that the inclusion of
all analgesic drug groups is essential to understand the
trends of analgesic consumption before and after joint
replacement. However, all these previous studies show
the user rates only one year pre- and postoperatively.
In this study, the user rates were analyzed two years be-
fore the surgery to find out at which point the propor-
tion of users starts to increase, and two years
postoperatively to find out whether analgesic use
stabilize one year after surgery. Patients with revision
or other joint replacement during the follow-up period
were excluded, so hip and knee pain on other joints
should not hamper the results. All operations were per-
formed in a single orthopedic hospital with a standard-
ized perioperative anesthesia and analgesia.
Register-based studies also have limitations. The
pharmacological dispensing data do not inform whether
the drug was redeemed because of pain in the operated
joint or whether the patient has taken the drug or not. A
daily diary of analgesic drug use could give more accurate
information on the topic. We did not analyze amounts of
drugs used, and inclusion of DDDs (defined daily dose) or
OMEQs (oral morphine equivalents) could give more in-
formation on this topic. However, the perceptions of pain
and the amounts of analgesics used are individual, and the
value of reporting proportions of users is that it tells
whether there is need or no need for analgesics. We were
not able to analyze OTC drugs and topical NSAIDs that
may have been used in addition to or instead of prescrip-
tion analgesics and hence the actual use of analgesics may
have been even greater than we observed. In the case of ir-
regular use, purchases of analgesics can occur with longer
intervals, and therefore the proportion of users may be
underestimated in studies based on register data. A multi-
joint osteoarthritis is one confounding factor and we were
not able to analyze pain on non-target joints. The intensity
of pain and the prevalence of persistent pain could not be
evaluated in this study. Although the population was un-
selected and included all the patients of the region, the
generalizability of the results may be limited, because all
surgeries were performed in the same hospital, and both
indications for joint replacement and prescription prac-
tices may vary in different regions even though there are
national guidelines for both. It should be noted that due
to the large sample size, even minor differences may ap-
pear statistically significant.
Conclusions
In conclusion, the use of analgesic drugs increases before
joint replacement surgery, and both hip and knee re-
placement lead to reduction in the use of pain medica-
tions, although the change is lesser after knee
replacement. The reductions in the user rates were simi-
lar for acetaminophen, NSAIDs and opioids whereas use
of medications for neuropathic pain seems to increase
slightly. A substantial number of patients continue to
use analgesics up to two years after surgery.
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